Huperzine A: Benefits, Forms, Dosing, and Side Effects

Table of Contents

• Current evidence position
• Key safety points
• Brad's videos on this topic
• Overview
• Forms and Bioavailability
• Evidence for Benefits
• Recommended Dosing
• Safety and Side Effects
• Drug Interactions
• Dietary Sources
• References

Current evidence position

Brad has not made a video on this topic; this is a summary of the evidence, not his view. Reviews of mostly small Chinese trials in Alzheimer's disease found that huperzine A improved cognitive test scores and daily function, but most trials had a high risk of bias, and a 2008 Cochrane review found only one study of adequate quality and size ^{[26, 58]}. The largest Western trial gave 210 people with mild to moderate Alzheimer's disease 200 mcg or 400 mcg of huperzine A twice daily; the 200 mcg dose did not improve cognition, and the 400 mcg dose helped only in secondary analyses ^[16]. Huperzine A blocks the same enzyme as the dementia drug donepezil, and drugs of this kind are linked to fainting and a slow heart rate in older people, so anyone taking dementia drugs, anticholinergic drugs or heart-rate-lowering medicines, or with a heart rhythm problem, should talk to their doctor first ^{[3, 68, 69]}. Supplements are unreliable: in a 2020 analysis of 22 products, only two held within 10% of the huperzine A declared on the label ^[48].

Brad's videos on this topic

None yet.

1. Overview

Huperzine A is an alkaloid first isolated from the Chinese club moss Huperzia serrata, a traditional Chinese medicine called Qian Ceng Ta ^{[2, 46]}. It is a potent, highly specific and reversible inhibitor of acetylcholinesterase (AChE), the enzyme that breaks down the messenger chemical acetylcholine ^[3]. Blocking AChE leaves more acetylcholine in the brain, which is how it is thought to help memory ^[58].

Plants of the same family have been used in China for contusions, strains, swellings, schizophrenia, myasthenia gravis and organophosphate poisoning ^[2]. Huperzine A is a licensed Alzheimer's drug in China and is sold as a supplement in the US ^[11].

Beyond blocking AChE, cell and animal studies suggest other actions ^{[3, 11]}:

• NMDA receptor antagonism: It blocks NMDA receptors and potassium currents, which may add to its protection of nerve cells ^[3].
• Antioxidant properties: It reduces oxidative stress and protects mitochondria ^{[3, 11]}.
• Beta-amyloid modulation: It interferes with the processing of amyloid precursor protein and acts on Wnt signalling ^{[3, 75]}.
• Neuroprotection against ischemia: It protects cells against damage from ischemia, glutamate and hydrogen peroxide, and regulates the apoptosis proteins Bcl-2, Bax, P53 and caspase-3 ^[3].

Most of this evidence comes from the lab. Whether huperzine A slows Alzheimer's disease in people is unproven ^[11].

2. Forms and Bioavailability

Natural vs. Synthetic Huperzine A

Huperzine A exists as two mirror-image forms. The natural (-)-form is the active one: in rat brain tissue it blocked AChE 38-fold more strongly than the (+)-form ^[14].

Synthetic huperzine A is often a racemic mix of both forms. In lab tests the racemic mix was two- to three-fold less potent than natural (-)-huperzine A ^{[14, 66]}. A label that does not say which form a product holds may overstate its active dose.

Standardized Extracts

Chinese trials used tablets or capsules holding 50 mcg each, and in one 60-day trial in Alzheimer's disease the capsules and tablets worked equally well ^[64]. Only 2 of 22 products tested held within 10% of the labelled amount (see Supplement Quality Concerns) ^[48].

Pharmacokinetics

Huperzine A is absorbed quickly, spreads widely through the body and is cleared at a moderate rate ^{[3, 21]}:

Absorption: In 12 healthy volunteers given a single 0.4 mg tablet, it appeared in the blood within 5-10 min and peaked at a mean of 58.33 min ^[19]. In six volunteers given 0.99 mg, the peak came at 79.6 min ^[21].

Distribution: It crosses the blood-brain barrier better than tacrine, donepezil and rivastigmine, and has higher oral bioavailability ^[3].

Metabolism: Human liver microsomes did not break it down within 90 min, and it had negligible effects on the main CYP enzymes, so interactions through these enzymes are unlikely ^[22].

Elimination: In healthy men, the half-life averaged 12.092 h ^[65]. In older adults given 0.1 mg, 35% of the dose was excreted unchanged in urine within 48 h ^[22].

Comparison with Prescription AChE Inhibitors

Compared with tacrine, donepezil and rivastigmine, huperzine A blocks AChE for longer ^[3]. In rats, it was 8- and 2-fold more potent than donepezil and rivastigmine, molecule for molecule, at raising acetylcholine in the brain cortex, and its effect lasted longest ^[23]. Donepezil, but not huperzine A, caused muscle twitching in that study ^[23].

Binding Mechanism

The crystal structure of AChE bound to huperzine A, solved at 2.5 A resolution, shows the drug sitting in the enzyme's active-site gorge in an unexpected orientation ^[24]. Few strong direct bonds hold it; hydrophobic contacts with aromatic amino acids matter most ^[24]. The binding is reversible ^[3].

3. Evidence for Benefits

Alzheimer's Disease

Alzheimer's disease is the most studied use, with several randomised trials and meta-analyses, mostly from China ^[26].

Chinese multicentre trial (n=202): A 12-week placebo-controlled trial at 15 centres in China gave 202 people with mild to moderate Alzheimer's disease 400 mcg of huperzine A a day or placebo. A gain of at least 4 points on the ADAS-Cog cognitive scale occurred in 56.1% of the huperzine A group and 12.5% of the placebo group ^[25]. In an earlier 8-week Chinese trial, 29 of 50 people given 0.2 mg twice a day improved in memory, cognition and behaviour, against 19 of 53 on placebo ^[63].

US Phase II Multicenter Trial (n=210): A US trial randomised 210 people with mild to moderate Alzheimer's disease to placebo or huperzine A at 200 mcg or 400 mcg twice daily for at least 16 weeks ^[16]. The 200 mcg dose, the main test, did not change ADAS-Cog scores at 16 weeks. In secondary analyses, 400 mcg twice daily gave a 2.27-point ADAS-Cog improvement at 11 weeks, against a 0.29-point decline on placebo (p = 0.001); at week 16 the gap was smaller (1.92-point vs 0.34-point improvement, p = 0.07) ^[16]. Global ratings, behaviour and daily living did not change at either dose ^[16].

2008 Cochrane review (6 RCTs, n=454): Six trials with 454 patients found that huperzine A improved MMSE scores compared with placebo (WMD 2.81; 95% CI 1.87 to 3.76), along with function and global ratings ^[58]. Only one study was of adequate quality and size, and the authors found the evidence inadequate to make any recommendation ^[58].

2013 Meta-Analysis (20 RCTs, n=1,823): A review of 20 trials with 1,823 participants found benefits on MMSE at 8, 12 and 16 weeks and on daily living activities, but most trials had a high risk of bias and the authors urged caution ^[26].

2014 Updated Meta-Analysis (10 RCTs): Eight Alzheimer's trials (733 participants) and two vascular dementia trials (92 participants) showed better MMSE and daily living scores, and longer treatment gave more benefit in Alzheimer's disease ^[27].

2009 Meta-Analysis (4 RCTs): Four trials found that 300-500 microg daily for 8-24 weeks improved MMSE and daily living scores, with no serious adverse events ^[59].

Limitations of the evidence base: Most trials were small, short and from China, and reviewers rated their methods poorly ^{[26, 58]}. Whether huperzine A changes the course of the disease is unproven ^[11].

Vascular Dementia

Evidence in vascular dementia (multi-infarct dementia) is mixed.

Chinese placebo-controlled trial (n=78): In a 12-week trial of 78 people with mild to moderate vascular dementia, huperzine A 0.1 mg twice a day improved MMSE, CDR and daily living scores, while the vitamin C placebo group did not change; no serious adverse events were recorded ^[61].

Meta-analytic data: The 2014 meta-analysis pooled two vascular dementia trials and found better MMSE and daily living scores ^[27]. A 2009 Cochrane review, which could include only one small trial of 14 participants, found no significant benefit on MMSE (WMD 2.40; 95% CI -4.78 to 9.58) and called for more research ^[60].

Senile and Pre-Senile Dementia

An older Chinese trial gave huperzine A by intramuscular injection, not by mouth: 0.05 mg twice a day for 4 weeks to 56 people with multi-infarct or senile dementia, and 0.03 mg twice a day for 2 weeks to 104 people with senile and presenile memory disorders ^[46]. Memory scores improved significantly compared with saline injections ^[46]. A 2012 Cochrane review found no placebo-controlled trials of huperzine A in mild cognitive impairment ^[62].

Memory Enhancement in Healthy Adolescents

Adolescent memory trial (34 matched pairs): In a double-blind trial, 34 matched pairs of junior middle school students who said their memory was poor took two 50 mcg capsules of huperzine A or placebo twice daily for 4 weeks ^[32]. Memory quotient scores ended higher with huperzine A (115 vs 104) ^[32]. The trial was small and short, so larger trials are needed before drawing conclusions.

Traumatic Brain Injury

US TBI Trial: A US phase II randomised, double-blind pilot trial in moderate to severe traumatic brain injury found no difference in memory between huperzine A and placebo after 12 weeks ^[33]. Learning and memory improved significantly in the placebo group, and the authors explained the gains in both groups as a placebo effect ^[33].

Myasthenia Gravis

Huperzine A has been given to people with myasthenia gravis in China, and plants of its family were used for the disease in traditional medicine ^{[2, 46]}.

Epilepsy (Preclinical Only)

In mice, huperzine A at 0.56 or 1 mg/kg protected against seizures induced by 6 Hz stimulation, pentylenetetrazole and maximal electroshock, including in mouse models of Dravet syndrome ^[36]. Muscarinic and GABA-A receptors played a role ^[36]. These preclinical findings remain to be validated in human trials.

Organophosphate Poisoning and Nerve Agent Protection (Preclinical)

Huperzine A binds AChE reversibly and crosses into the brain, so it has been tested as a pretreatment to protect AChE from nerve agents such as soman ^[38]. A 2002 review concluded it has value for this use and appears free of harmful effects in healthy subjects ^[38].

Parkinson's Disease (Preclinical Only)

In mice with MPTP-induced Parkinson's-like disease, huperzine A injection improved movement, learning and memory, and protected dopamine-producing neurons ^[40]. Human studies are needed.

Neuroprotection Against Beta-Amyloid Toxicity (Preclinical)

Lab studies show huperzine A protects neurons against beta-amyloid-induced oxidative injury and mitochondrial dysfunction ^[11]. Whether this slows Alzheimer's disease in people is unproven ^[11].

Combination with Prescription AChE Inhibitors

Huperzine A acts on the same enzyme as donepezil, rivastigmine and galantamine ^{[3, 69]}. Taking them together may add to cholinergic side effects, so combine them only on your doctor's advice (see Drug Interactions).

Summary of Clinical Evidence

4. Recommended Dosing

Dosing by Indication

These doses come from clinical trials:

Alzheimer's disease (mild to moderate): Chinese trials used 400 mcg a day, often as 0.2 mg twice a day, for 8 to 12 weeks ^{[25, 63]}. The 2009 meta-analysis covered 300-500 microg daily for 8-24 weeks ^[59]. The US trial tested 200 and 400 mcg twice daily; only the higher dose showed any benefit, in secondary analyses ^[16].

Vascular dementia: 0.1 mg twice a day for 12 weeks in the positive trial ^[61].

Senile and presenile memory disorders: The doses used (0.03 mg and 0.05 mg twice a day) were intramuscular injections, so they do not translate to supplement doses ^[46].

Memory enhancement (healthy individuals): The one adolescent trial used 100 mcg twice daily for 4 weeks ^[32].

General cognitive support (supplement use): No dose is established for general memory support; the only trial in healthy people studied adolescents ^[32].

Practical Dosing Considerations

Timing: The long half-life (see Pharmacokinetics) suits twice-daily dosing, which most trials used ^{[16, 25, 61]}.

Form selection: Natural (-)-huperzine A is more potent than the racemic synthetic mix ^{[14, 66]}, so a racemic product holds less active drug than the same labelled amount of the natural form.

Dose Comparison with Prescription AChE Inhibitors

Direct dose comparisons come from rats: huperzine A raised acetylcholine in the brain cortex at 0.25-0.75 micromol/kg, against 2-6 micromol/kg for donepezil ^[23].

5. Safety and Side Effects

Overall Safety Profile

In trials, side effects were mostly mild and cholinergic. The 2008 Cochrane review found no significant difference in adverse events between huperzine A and control groups, and the 2013 meta-analysis found no trial reporting severe adverse events ^{[26, 58, 59]}.

Common Side Effects

Most adverse effects are mild, transient, and related to huperzine A's cholinergic mechanism of action ^{[27, 59]}:

• Nausea: Mild to moderate nausea was the only notable side effect in a 60-day trial ^[64].
• Dizziness: A few patients in an older trial felt slight dizziness ^[46].
• Insomnia and ankle swelling: These were mild and short-lived, and affected 3% of the huperzine A group in the Chinese multicentre trial ^[25].

Less Common Side Effects

Drugs that block AChE can slow the heart and cause fainting (see Cardiac Effects) ^[68].

Dose-Related Effects

The US trial's highest dose was 400 mcg twice daily, given for at least 16 weeks ^[16]. An overdose may cause cholinergic poisoning, as club moss tea did (see Cholinergic Crisis) ^[67].

Discontinuation Rates

In the US trial, 177 of the 210 people randomised completed the treatment phase ^[16].

Cholinergic Crisis (Overdose)

Two people drank tea made by mistake from fir club moss (Lycopodium selago) and developed sweating, vomiting, diarrhoea, dizziness, cramps and slurred speech ^[67]. The plant held enough huperzine A to explain the poisoning, and the authors expected atropine to help ^[67].

If someone has these symptoms after taking huperzine A, or faints or has trouble breathing, call your local emergency number (111 in NZ, 000 in Australia, 911 in the US, 999 in the UK) or go to the emergency department.

Cardiac Effects

Cholinesterase inhibitors can slow the heart. In older adults with dementia in Ontario, Canada, those taking these drugs had more hospital visits for fainting (HR 1.76; 95% CI 1.57 to 1.98) and for slow heart rate (HR 1.69; 95% CI 1.32 to 2.15), and more pacemaker insertions and hip fractures, than those who were not ^[68]. That study looked at prescription drugs; huperzine A acts on the same enzyme ^[3]. Use it with caution if you have heart disease, a slow pulse or a heart rhythm problem, and ask your doctor first. If you faint, or have a very slow pulse with dizziness, chest pain or breathlessness, call your local emergency number (111 in NZ, 000 in Australia, 911 in the US, 999 in the UK) or go to the emergency department.

Conditions That May Be Worsened

Donepezil, which blocks the same enzyme, carries these cautions; they may also apply to huperzine A ^[77]:

• Peptic ulcer disease: Drugs of this kind may raise stomach acid, so people with a past ulcer or on NSAIDs should be watched for bleeding ^[77]. In older Swedish adults, cholinesterase inhibitors alone did not raise peptic ulcer risk (IRR 1.0, 0.9 to 1.2), but with NSAID painkillers the risk rose more (IRR 9.0, 6.8 to 11.8) than with NSAIDs alone (IRR 5.2, 4.4 to 6.0) ^[74].
• Asthma and COPD: Drugs of this kind call for care with asthma or obstructive lung disease ^[77]. A small chart review found a trend to more COPD flare-ups in the first 90 days (10 of 52 vs 3 of 42; P = 0.133) ^[71], but a large Ontario cohort found no higher risk of exacerbations (RR 1.02; 95% CI 0.91, 1.15) ^[72]. With asthma or COPD, ask your doctor first.
• Urinary tract obstruction: Drugs of this kind may cause bladder outflow obstruction, though donepezil trials did not show it ^[77]. They have also been linked to new or worsening urinary incontinence ^[70]. With a bladder outlet blockage, ask your doctor first.
• Epilepsy: Drugs of this kind are thought to carry some seizure risk, though Alzheimer's disease itself can cause seizures ^[77]. A Korean study of older adults with dementia found no statistically significant association overall between how long people took them and seizure risk; one comparison suggested a slight rise after a year of donepezil ^[73]. With epilepsy, ask your doctor first.

Long-Term Safety

Most trials lasted 8-24 weeks, so data on longer use are limited ^[59].

Pregnancy and Lactation

There is insufficient evidence on the safety of huperzine A during pregnancy and lactation. Use is not recommended in these populations.

Special Populations

Elderly patients: Fainting, slow heart rate and hip fracture were more common in older adults with dementia taking prescription cholinesterase inhibitors ^[68].

Renal impairment: In older adults, 35% of a dose left the body unchanged in urine within 48 h, so the kidneys clear much of it ^[22]. With significant kidney disease, ask your doctor before using it.

Supplement Quality Concerns

A 2020 laboratory analysis of 22 supplements labelled as containing huperzine A found ^[48]:

• Only two held huperzine A within 10% of the declared amount; measured amounts ranged from below the limit of quantification to 267.1 µg/serving.
• Sixteen (73%) had at least one labelled ingredient that the analysis did not detect, and 16 (73%) held compounds not on the label.
• Nine (41%) listed ingredients that do not meet FDA rules for supplement ingredients. Stimulants detected included higenamine and halostachine, and also hordenine, an ingredient on an FDA advisory list.

Products with independent third-party testing may lower these risks; consumerlab.com and Labdoor test some supplements.

6. Drug Interactions

Cholinergic Drugs (Major Interaction)

Huperzine A blocks AChE, as do the dementia drugs donepezil, rivastigmine and galantamine ^{[3, 69]}. Taking it with them, or with other drugs that boost acetylcholine, may add to cholinergic effects ^[77]. Examples:

• Succinylcholine and similar muscle relaxants used in anaesthesia, whose effect these drugs may exaggerate ^{[69, 77]}
• Dementia drugs: donepezil, rivastigmine, galantamine
• Myasthenia gravis drugs that block the same enzyme, such as pyridostigmine and neostigmine ^[77]
• Bethanechol, which stimulates acetylcholine receptors directly ^[77]

Signs of excess cholinergic effect include sweating, vomiting, diarrhoea, dizziness, cramps and slurred speech ^[67]. For severe symptoms, call your local emergency number (111 in NZ, 000 in Australia, 911 in the US, 999 in the UK) or go to the emergency department.

Anticholinergic Drugs (Opposing Interaction)

Anticholinergic drugs block acetylcholine, so they and huperzine A may weaken each other ^[77]. A review of dementia drug interactions lists anticholinergic drugs among the main concerns for cholinesterase inhibitors ^[69]. In older adults with dementia, starting a cholinesterase inhibitor was linked to a higher chance of then receiving an anticholinergic drug for urinary incontinence (adjusted hazard ratio, 1.55; 95% confidence interval, 1.39-1.72), which may be one drug treating the side effect of another ^[70]. Examples:

• Bladder medicines such as oxybutynin and tolterodine
• Sedating antihistamines such as diphenhydramine and chlorpheniramine

Beta-Blockers (Cardiac Interaction)

Cholinesterase inhibitors can slow the heart, and a review lists bradycardia-inducing drugs, such as beta-blockers, among their main interaction concerns ^{[68, 69]}. If you take a beta-blocker or another heart-rate-lowering drug, ask your doctor before using huperzine A.

Pharmacokinetic Considerations

In lab tests it barely affected CYP enzymes, so it is unlikely to change blood levels of other drugs ^[22].

General Recommendation

Check with your doctor before taking huperzine A alongside any prescription medicine, especially:

• Any drug for Alzheimer's disease or dementia
• Medications for myasthenia gravis
• Heart rate-lowering drugs (beta-blockers, calcium channel blockers, digoxin)
• Anticholinergic medications
• Older (conventional) antipsychotics, which a review lists among the main interaction concerns ^[69]
• Anesthetics (succinylcholine)

7. Dietary Sources

Natural Sources of Huperzine A

Huperzine A is not obtained through normal dietary intake. It comes from club mosses of the Huperziaceae family ^[2]:

Primary source, Huperzia serrata (Chinese club moss): The plant from which huperzine A was first isolated and the main source of the Chinese medicine ^{[2, 46]}.

Secondary sources:

• Huperzia selago: The European fir club moss (also called Lycopodium selago) holds enough huperzine A to poison people who brew it as tea by mistake ^[67].
• Phlegmariurus species: Members of this genus are also used as medicines in China ^[2].

Sustainability Concerns

Huperzia serrata is an endangered Chinese medicinal plant ^[76]. Growing it from tissue culture in the lab may ease pressure on wild plants, and lab-grown tissue still made huperzine A ^[76].

Chemical Synthesis

Chemists can make racemic huperzine A in quantity, but in the lab the racemic mix was 3 times less potent than natural (-)-huperzine A ^[66].

Biosynthesis in Plants

In 2023, researchers identified carbonic anhydrase-like enzymes that club mosses need to build the core of their alkaloids, and described the later steps that tune huperzine A's ability to block AChE ^[53].

Practical Implication

Because huperzine A cannot be obtained from food, supplementation is the only option for individuals seeking it.